| P50 | author | David M. Holtzman | Q56827171 |
| | John C. Morris | Q56839763 |
| | Jin-Moo Lee | Q60375280 |
| P2093 | author name string | J H Ladenson | |
| | R Tarawneh | |
| P2860 | cites work | Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI | Q80071452 |
| | The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? | Q28190980 |
| | Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients | Q28199980 |
| | Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 |
| | The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 |
| | Semantic memory and the brain: structure and processes | Q30647714 |
| | The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers | Q31081008 |
| | Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. | Q33942382 |
| | Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease | Q35158065 |
| | The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients | Q37166782 |
| | MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change | Q37273569 |
| | Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. | Q37366280 |
| | Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type | Q37381205 |
| | Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention | Q37438267 |
| | Longitudinal study of the transition from healthy aging to Alzheimer disease | Q37481504 |
| | Episodic and semantic memory in mild cognitive impairment | Q38414675 |
| | Screening for dementia by memory testing | Q38486281 |
| | Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 |
| | Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease | Q40766817 |
| | CSF biomarkers predict rate of cognitive decline in Alzheimer disease. | Q43254482 |
| | In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life | Q44605297 |
| | Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain | Q44810166 |
| | Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease | Q48214669 |
| | Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 |
| | Identification of novel brain biomarkers. | Q48466456 |
| | Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype | Q48499517 |
| | Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease | Q48790608 |
| | CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment | Q48932241 |
| | Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. | Q51664967 |
| | Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. | Q51983988 |
| | Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 |
| | Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. | Q52424284 |
| | Protection against Alzheimer's disease with apoE epsilon 2. | Q53204350 |
| | Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 709-719 | |
| P577 | publication date | 2012-02-22 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease | |
| P478 | volume | 78 | |